November 30th, 2023

Life Sciences BC seeks to raise the profile of our members and supporters, highlight their achievements, and promote BC's dynamic life sciences ecosystem. If you have news or a story to share, let us know.

You can find previous editions of BioLinks newsletters and other resources on our website at News/Publications.

Life Sciences BC News

I was delighted to attend the Clinical Trials BC Symposium 2023: Approaches for Accessible Clinical Trials this week, which provided an invaluable platform for BC's clinical trials community to exchange insights and collaboratively explore strategies to advance our ecosystem and promote healthcare across the province. This year's focus on innovative approaches, technology, pathways, and regulatory initiatives reflects a shared commitment to improving the accessibility of clinical trials. Kudos to Alison Orth, Jean Smart, and Dr. Bev Holmes - and the whole team at Michael Smith Health Research BC and Clinical Trials BC - for hosting such an outstanding event! Also pictured are Darryl Knight of Providence Health Care, Robert Olson of UBC and BC Cancer, and Julia Bickford of Northern Health.

I also had the privilege this week of attending the grand opening of Incisive Genetics' new wet lab space! Congratulations to Pamela Wagner, Dr. Blaire Leavitt, Austin Hill and Board Chair Noel Hall - and the whole IG team - on this exciting development!

We eagerly look forward to attending the J.P. Morgan Conference this January! If you also plan to attend and find yourself overwhelmed by the MANY options during JPM Week, don't miss our virtual Blakes Breakfast Speaking Series: Preparing for J.P. Morgan Week event on Dec. 13.

We are bringing together a great lineup of sector leaders and experienced conference-goers, including LSBC Board Chair Ali Ardakani of Novateur Ventures, Christian Barrow of J.P. Morgan, Allison Gaw of Amplitude Ventures, Mackensie Vernetti of BIO, and more!

Novateur Ventures, in collaboration with the Biotechnology Innovation Organization (BIO), is offering a complimentary 2024 J.P. Morgan Week Event Guide Mobile App to enhance your conference experience. Adding your event to the app is free, and you can download it here.

Don't forget to let us know if you're attending the conference, and we'll ensure you're included in our BC company guide!

Member Highlights 

adMare BioInnovations has released its first white paper, "Canada's Evolving Life Sciences Industry: Exploring Ecosystems, Clusters, and the Need for Anchor Companies," which examines the pivotal roles played by innovation clusters and anchor companies in driving the growth of the life sciences sector. Underscoring the importance of strong leadership, the paper emphasizes the significance of adopting a strategic approach to ensure the success of this dynamic and evolving industry. Read it here.

The Canadian Alliance for Skills and Training in Life Sciences (CASTL) has introduced its latest initiative, CASTL Elevate—a 10-week national training program crafted to empower individuals to launch their careers in the biomanufacturing industry. With support from Upskill Canada, CASTL aims to train up to 400 new biomanufacturing workers, equipping them with in-demand technical and essential skills for fulfilling careers in this innovative sector. Learn more about CASTL Elevate here. 

Augurex is announcing the availability of prime turn-key lab and office space within its shared premises on Jan.1, 2024. Interested parties are encouraged to contact Alain Rivere at CBRE. Learn more.

St. Paul's Foundation has launched this year's Lights of Hope celebration—an initiative dedicated to raising funds for research, patient care, and life-enriching activities for residents in long-term care across Providence Health Care. Contribute to this meaningful cause and learn more here.

Invest Vancouver has released its Strategic Industries Analytics Report, identifying the rising stars in the region's industries and spotlighting the life sciences sector, which is notably outpacing the broader regional economy across key economic indicators. Read it here.

In groundbreaking news, a stem cell-based treatment for Type 1 diabetes has been detailed in recent clinical trial results published in Nature Biotechnology by UBC and Vancouver Coastal Health Research Institute. The treatment demonstrates the ability to regulate blood sugar levels and decrease reliance on insulin injections. These findings suggest the potential development of a therapy that could eventually eliminate the need for daily insulin injections. Learn more about this revolutionary advancement here.

New Members

TMX, comprising the Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSXV) (the "Exchange"), provides companies with access to equity capital and the benefits of being listed on a leading global exchange.

IPS Canada meets the needs of local and multi-national clients by offering subject matter expertise and single-source EPCMV (Engineering, Procurement, Construction Management, and Validation) project delivery services.

Welcome all to the LSBC community!

Industry Highlights

The BC Centre for Innovation and Clean Energy (CICE) is offering $75,000 in early-stage funding to twelve BC-based ventures that recently graduated from university entrepreneurship programs. This initiative aims to support ventures transitioning from early solution validation to developing a commercialization strategy in the clean energy and climate solutions sector. Applications for the 2024 University Call for Innovation are open from Jan. 22 to Mar. 4, 2024, in collaboration with institutions that include SFU VentureLabs, entrepreneurship@UBC-V, entrepreneurship@UBC-O, UNBC Innovation Program, and UVic Coast Capital Innovation Centre. Learn more.

The Global Biodata Coalition is actively seeking feedback on two consultation papers addressing challenges in sustaining biodata resources and implementing open data policies in the life and biomedical sciences. Open for input until Dec. 4, 2023, this inclusive consultation invites input from diverse communities, including funders, infrastructure providers, data users, and policy bodies. The papers present options for collaboration to address funding and data complexities. Insights gathered during this phase will help shape subsequent white papers outlining strategies for sustaining global biodata infrastructure. To engage in this important discourse and contribute your feedback, click here.

Kudos

Congratulations to Drs. Kayla King, Isla Myers-Smith, and Corey Stephenson on their recent appointments as UBC's newest Canada Excellence Research Chairs. These internationally recognized scientists are engaged in significant research, from studying disease dynamics in the context of climate change to developing conservation strategies for ecosystems and creating more efficient and sustainable processes in medicine and agriculture. Learn more about their impactful work here.

Kudos to Andrew Martindale of UBC for receiving the Social Sciences and Humanities Research Council's 2023 Connection Award, recognizing his interdisciplinary work with Indigenous communities, focusing on legal systems and rights, as well as his use of geoarchaeology to locate unmarked graves, aiding efforts to find missing children from Indian Residential Schools. Learn more.

Congrats to Canary Medical, a finalist in the Fierce Health Life Sciences Innovation Awards 2023, for its canturio™te product included on the Digital Health Solutions list. See the complete list of honourees here.

Congratulations to Aspect Biosystems for earning a spot on Fast Company's third annual Next Big Things in Tech list, recognizing technological breakthroughs poised to shape the future across various industries, including healthcare, security, artificial intelligence, and data. Aspect Biosystems has been acknowledged for its innovative approach to regenerative medicine and treating challenging diseases through its comprehensive tissue therapeutic platform. Learn more. See the complete list of winners here.

Kudos to Aurinia Pharmaceuticals, nominated for the Prix Galien USA 2023 Award in the Best Pharmaceutical Product category, recognizing unique medical products, devices, and individuals who have impacted patient care through innovation. Learn more and see the complete list of nominees here.

Congrats to VoxCell BioInnovation, a finalist in Meet the Drapers Season 6! See their pitch and cast your vote here. (Brazil (Rio de Janeiro) section). VoxCell BioInnovation has also been selected as a finalist for the Startup of the Year award at the 2023 VIATEC Community Awards, which will take place on Nov. 30!

Kudos to Dr. Zahra Shayegan, the inaugural recipient of the National Research Council of Canada's Luise and Gerhard Herzberg Postdoctoral Fellowship awarded to outstanding women in STEM.  Zahra recently joined the NRC's Materials for Clean Fuels Challenge program at Vancouver's Energy, Mining, and Environment Research Centre. Learn more about her inspiring career here. 

People on the Move

We wish to express our gratitude to Kirk LaPointe, outgoing Publisher and Executive Editor of Business in Vancouver (BIV) and Vice President of Glacier Media, for his commitment and leadership over the years in service to the British Columbia business and life sciences community. We also wish to acknowledge his invaluable contributions as a key collaborator in our annual life sciences magazine.

We extend our warmest congratulations to Hayley Woodin Hastings, who assumed the role of BIV Editor-in-Chief in January 2023. Stepping into an elevated leadership position at BIV and within Glacier Media, Hayley brings a wealth of experience to her new portfolio. We look forward to continuing our fruitful collaboration with BIV under Hayley's guidance and leadership. For further details, click here.

HtuO Biosciences welcomes Jason Loscher as its new Director of Technology.

Applications Open

For those interested in Michael Smith Health Research BC’s 2024 Research Trainee competition but missed the info webinar, the recording is now available here.

Eureka Network, the world’s biggest public network for international cooperation in R&D and innovation, present in over 45 countries, has an ongoing list of funding opportunity calls for projects in Canada. See the list here.

SMART EUREKA CLUSTER offers research funding for collaborative international R&D projects in advanced manufacturing. This initiative, available in Canada through NRC IRAP, promotes global collaboration in R&D&I projects for the vital European manufacturing sector. The deadline for proposals is Apr. 22, 2024. Learn more here.

The CIHR Canadian HIV Trials Network 024/25 Postdoctoral Fellowship Awards competition, which facilitates research in HIV, hepatitis C (HCV) and other sexually transmitted and blood-borne infections (STBBIs) and related health conditions, is open for applications. The deadline to apply is Dec. 14. Learn more here.

The Canadian Institutes of Health Research seeks applicants to its Governing Council to help shape its strategic directions, goals, and policies. Applications are due Dec. 15. Learn more.

The Marathon of Hope Cancer Centres Network has launched its funding competitions for early career researchers for 2024. The MOHCCN Clinician-Scientist Awards will provide outstanding young clinician investigators with funding to support high-quality research in precision oncology (LOI Deadline Dec. 18), and the Health Informatics & Data Science Awards will provide outstanding young researchers in health informatics and related fields with funding to support high-quality research in precision oncology (applications due Feb. 2, 2024.) Learn more.

Upcoming LSBC events and programs at-a-glance

Jan. 16/17 - LSBC, in partnership with Biotech Primer, is pleased to present BioBasics 201: Targeted Biologics for the Non-Scientist, a follow-up to BioBasics 101.

Jan. 26 - Attention life sciences employers, post-secondary students, and job seekers! We are pleased to announce our fifth annual Career Connect Day on January 26, 2024.

We're thrilled to announce that we are one of the delivery partners for the new AccelerateIP (AIP) program, which helps startups leverage the potential of their IP.



Until next week,

Wendy and the LSBC team

Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

Clairvoyant Therapeutics Inc., the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints... READ MORE

InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration

Results from a study, conducted under a collaborative research agreement with leading cannabinoid expert Dr. Mauro Maccarrone at the Università degli Studi dell’Aquila (Italy), demonstrated that INM-089 preserved retinal function in an in vivo AMD disease model... READ MORE

Phyton Biotech Announces Acquisition of Controlled Substances Dealers License From Health Canada

Phyton Biotech LLC. proudly announces a significant milestone in its journey toward advancing pharmaceutical research and development. The Company is pleased to announce the receipt of its Controlled Substances Dealers License (CSDL) from Health Canada, effective November 2023. This pivotal license empowers Phyton Biotech to engage in groundbreaking work with psilocin and psilocybin... READ MORE

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that Health Canada has granted Market Authorization for the expanded use of PrKALYDECO® (ivacaftor) for the treatment of cystic fibrosis (CF) in children ages 2 months and older weighing at least 3 kg who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR)... READ MORE

Xenon Pharmaceuticals Announces Proposed Public Offering

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced that it has commenced an underwritten public offering of $225.0 million of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement... READ MORE

adMare BioInnovations Welcomes 22 Influential Life Sciences Leaders to Cohort VI of the adMare Academy Executive Institute

adMare BioInnovations (adMare) is pleased to welcome 22 life sciences leaders to Cohort VI of the adMare Academy’s Executive Institute. The adMare Academy’s high-value, high-impact talent development programs build the essential personnel needed to drive the Canadian life sciences ecosystem. The Executive Institute is an eight-month, custom-designed executive development program... READ MORE

Aspect Biosystems Named to Fast Company’s 2023 List of the Next Big Things in Tech

Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of disease, announced that it has been named to Fast Company’s third annual Next Big Things in Tech list, honoring technological breakthroughs that promise to shape the future of industries — from healthcare and security to artificial intelligence and data... READ MORE

LifeLabs Kimberley, BC, Relocates and Announces Grand Opening of Expanded Patient Service Centre

LifeLabs, Canada’s leading provider of medical diagnostic services and recognized as the most trusted brand in health diagnostic services by Canadians, is thrilled to announce the relocation and grand opening of its brand-new facility in Kimberley, B.C. on Tuesday, November 28, 2023. The Kimberley Patient Service Centre (PSC) is now located at 315 Wallinger Ave, Suite #5, Kimberley, BC, and promises an enhanced experience, expanded services, and convenient access for the local community... READ MORE

Pfizer Canada, Colorectal Cancer Canada and Thermo Fisher Scientific Announce Recipients of Colorectal Cancer Grant

Pfizer Canada, Colorectal Cancer Canada and Thermo Fisher Scientific are proud to announce the recipients who will collectively receive over $300,000 in grants for quality improvement initiatives to empower Canadian healthcare centres without in-house molecular testing capacity, and to improve molecular testing turnaround times for individuals with metastatic colorectal cancer and other advanced cancers... READ MORE

Stem Cell-Based Treatment Controls Blood Sugar in People With Type 1 Diabetes

An innovative stem cell-based treatment for Type 1 diabetes can meaningfully regulate blood glucose levels and reduce dependence on daily insulin injections, according to new clinical trial results from the University of British Columbia (UBC) and Vancouver Coastal Health (VCH)... READ MORE

CASTL Launches National Biomanufacturing Training Program Powered by Upskill Canada

The Canadian Alliance for Skills and Training in Life Sciences (CASTL) announces the launch of its national biomanufacturing skills and training program – CASTL Elevate. CASTL Elevate is powered by Upskill Canada, and is part of the first wave of partnership programs that are taking an industry-informed approach to supporting workers in Canada’s fast-growing biomanufacturing sector... READ MORE

Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA

Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s Hemophilia A program... READ MORE

The Benefits of Using NAVA on All Preterm Infant

Dr. Juyoung Lee, pediatrician in the Division of Neonatology at the Inha University College of Medicine in the Republic of Korea, routinely use Getinge’s innovation Neurally Adjusted Ventilatory Assist (NAVA) with diaphragm monitoring (Edi) on all preterm infants born in her unit... READ MORE

STEMCELL Technologies Wins a Canada’s Most Admired Corporate Cultures™ of 2023 Award

STEMCELL Technologies, Canada’s largest biotechnology company, has received the Canada’s Most Admired Corporate Cultures™ of 2023 award by Waterstone Human Capital. This national awards program recognizes best-in-class Canadian organizations for fostering high-performance corporate cultures that help sustain a competitive advantage... READ MORE

Filament Health Signs Non-Binding Term Sheet For Convertible Note In Connection With Planned Business Combination

Filament Health Corp., a clinical‐stage natural psychedelic drug development company, announced that the Company has signed a non-binding term sheet (the “Term Sheet”) providing for up to US$14.4 million in funding through a convertible note (the “Financing”) with an affiliate of Helena Partners Inc., a Cayman-Islands based advisor and investor (“Helena”)... READ MORE

BioTalent Canada’s Catalyst Award for Top New Hire Now Accepting Nominations

BioTalent Canada opened its call for nominations for the Catalyst Award for Top New Hire. Now in its ninth year, the award celebrates the achievements of young minds who are launching their careers in Canada’s bourgeoning health and biosciences sector. While the Catalyst Award is open to employers who have hired wage subsidy participants from all BioTalent Canada’s wage subsidy programs, recent winners, including 2023’s winner, Jade Bouchard, have come from participants in BioTalent Canada’s immensely popular Student Work Placement Program... READ MORE

Cracking the Code of Cellular Health: Dr. Vocadlo’s Pioneering Research

GlycoNet Investigator Dr. David Vocadlo is leading groundbreaking research unraveling the mysteries of a cellular process vital for maintaining overall cell health. The research team’s recent breakthrough towards understanding how certain proteins are modified by a sugar called N-acetylglucosamine (O-GlcNAc) has revealed a key factor at play—a specific amino acid sequence... READ MORE

ICORD is a world leading health research centre focused on spinal cord injury. From the lab-based cellular level of understanding injury to rehabilitation and recovery, our researchers are dedicated to the development of more effective strategies to promote prevention, functional recovery, and improved quality of life after spinal cord injury.

Located at Vancouver General Hospital in the Blusson Spinal Cord Centre, ICORD is supported by UBC Faculty of Medicine and Vancouver Coastal Health Research Institute. ICORD Principal Investigators, Investigators and Associate Members come together from many different departments at the University of British Columbia, Simon Fraser University, the B.C. Institute of Technology, and the University of Victoria, reflecting the wide breadth of expertise through the Centre. The Principal Investigators include five Chairs, established through the support of the Rick Hansen Foundation, and a variety of Canada Research Chairs, McLean Integrated Spine Clinic Scholars, and Canadian Institute of Health Research New Investigators.

ICORD research is anything from cellular to community level research that addresses a question concerning the promotion of improved functional outcomes and quality of life for people with spinal cord injury. ICORD’s research activities span the continuum from basic, preclinical discovery, to human-based discovery, to acute clinical interventions, to chronic care and rehabilitation, to community integration and participation.

LEARN MORE

B.C. Centre for Innovation and Clean Energy Partners with University Entrepreneurship Programs to Boost Start-up Venture Success

The B.C. Centre for Innovation and Clean Energy (CICE) is introducing a new funding avenue for emerging B.C.-based ventures that have recently graduated from university entrepreneurship programs. $75,000 in early-stage funding will be allocated to a maximum of twelve ventures nominated from leading universities across British Columbia: Simon Fraser University (SFU), University of British Columbia (UBC) campuses in Vancouver and the Okanagan, University of Northern British Columbia (UNBC), and University of Victoria (UVic)... READ MORE

AstraZeneca Launches Evinova, a Health-Tech Business to Accelerate Innovation Across the Life Sciences Sector, the Delivery of Clinical Trials and Better Health Outcomes

Evinova will prioritise bringing to market established and scaled digital technology solutions already being used globally by AstraZeneca to optimise clinical trial design and delivery. This will reduce the time and cost of developing new medicines, bring care closer to home for patients and reduce the burden on health systems. Evinova will also pursue opportunities in digital remote patient monitoring and digital therapeutics with a pipeline of digital innovations in these areas... READ MORE

Account Manager, proXimity

Reporting to the VP, proXimity, you possess a unique blend of clinical trial industry knowledge and general business acumen; a hard worker striving to enhance the experience of our existing customers and drive new business within our current customer base forward. You are part of the proXimity team ensuring we are reaching our business goals and targets for the proXimity software and ensuring the current proXimity customers are receiving an exception level of customer service...LEARN MORE

Clinical Trial Assistant

The clinical trial assistant supports various clinical operations tasks, including developing trackers, compiling essential documents for regulatory submissions, coordinating data evaluation, managing clinical program files, creating site-facing forms, documenting meeting minutes, participating in teams/committees, conducting literature research, tracking budgets and contracts, and serving as the primary contact for study-related communication with sites, vendors, and service providers...LEARN MORE

Senior Clinical Study Manager, Clinical Operations

The Senior Clinical Study Manager is responsible for the oversight, execution and success of Eupraxia clinical studies. The Study Manager works cross-functionally with internal functional leads and external contract research organizations (CROs) to ensure that studies are completed to agreed standards, timelines and budget. The role will develop and support the work of Eupraxia’s clinical operations across a range of products and in accordance with company policies, procedures and culture...LEARN MORE

Senior Program Manager

The Senior Program Manager is a pivotal leadership role within our organization. This individual will be responsible for the successful global development, registration, and launch of pharmaceutical products. This role involves managing a matrix team and providing oversight for all key functions and activities, ensuring alignment with our strategic objectives...LEARN MORE

Lead Clinical Research Associate, Clinical Operations

The candidate will achieve this by assessing the trial site and applicable personnel on an ongoing basis, adhering to protocol regulatory requirements, good clinical practice regulations, and standard operating procedures. They will also ensure compliance with the patient-consent processes, verifying the receipt, handling, accounting, storage conditions, and availability of clinical products under investigation...LEARN MORE

Senior Project Manager

The senior project manager manages concurrent projects, ensuring adherence to budget, resource allocation, scope, and schedule, utilizing formal Project Management methods, collaborating with cross-functional teams for stakeholder buy-in, while proactively assessing and addressing risks...LEARN MORE

Senior/Principal Scientist, Preclinical Pharmacology

At Abdera Therapeutics, we are looking for curious and committed individuals who are ready for the opportunity to transform the way people living with cancer can be treated. We are devoted to advancing novel treatment options that offer new hope to families facing devastating diagnoses. We are in search of team members who work collaboratively with a diverse group of colleagues, respectfully engaging one another while collectively and inclusively tackling any challenges we may face. We are building an exciting and fast paced company passionate about discovering and developing tomorrow’s most innovative cancer therapies...LEARN MORE

Research Associate

Reporting to the Manager, and under the guidance of a research supervisor, the Research Associate designs the experimental approaches for various stages of an applied research project, directs research assistants and/or students, and communicates the results to the research supervisor, thus contributing to the success of research programs and/or projects. The focus of the position is applied research work related to molecular biology and genetics, including use of typical sequencing protocols and instruments (for PCR, qPCR, SNP- and SSR-based genotyping), and related bioinformatic methods. This may include working with single or multiple stakeholders, single or several project deliverables, and the use of instrumentation...LEARN MORE

Senior Director Medical Affairs

The Director, Medical Affairs will be responsible for defining and implementing KOL strategies to develop and maintain positive KOL endorsement and product champions for Eupraxia in OA diseases. The role will also be responsible for leading Eupraxia medical education initiatives and conference activities...LEARN MORE

Quality Control Supervisor – Deeley Research Centre, Victoria

The Quality Control Supervisor will support the manufacturing, quality control and quality assurance activities for the BCCA’s Cancer Immunotherapy Program, at the BCCA's Deeley Research Centre (DRC). The Quality Control Supervisor will provide supervision of the Quality Control group, ensuring efficient, orderly and seamless operation of the quality control laboratory at the CFIL including resource scheduling...LEARN MORE

Research Associate II, Protein Engineering

The role involves active participation in protein purification for multispecific antibodies to support research. Responsibilities include characterizing protein therapeutics, designing and executing experiments for screening antibody-based therapeutics, troubleshooting methods, and analyzing data. The candidate must maintain an organized lab, adhere to scientific standards and OH&S regulations, and actively foster collaborative relationships within the organization...LEARN MORE

Research Associate II – Protein Sciences

As a Research Associate II in Protein Sciences within the Integrated Sciences group, your key responsibilities include supporting protein activities, assisting the antibody generation team, documenting results, collaborating across teams, and managing program timelines to advance therapeutic efforts. Join our motivated drug discovery team, dedicated to delivering transformative medicines to patients while fostering an innovative and collaborative environment...LEARN MORE

Research Associate II – Antibody Generation

As a Research Associate II in the Antibody Generation group, you'll be responsible for optimizing antibody generation platforms, identifying lead antibody candidates, collaborating across teams, documenting results, presenting data, supporting innovative research strategies, and fostering a culture of innovation and collaboration. Join our dedicated drug discovery team with a focus on delivering transformative medicines to patients...LEARN MORE

Associate Scientist – Molecular Biology, Integrated Sciences

As an Associate Scientist in the Integrated Sciences group, your key responsibilities involve developing innovative assay solutions, providing support to the antibody generation team, improving core platforms, documenting results, collaborating across functions, managing program timelines, and fostering innovation. We seek candidates passionate about innovation and technical challenges to join our motivated drug discovery team dedicated to delivering transformative medicines while maintaining a culture of respect and trust...LEARN MORE

Senior Scientist, Formulation

NanoVation Therapeutics (NTx) is looking for an innovative and collaborative Senior Scientist, Formulation to join our team. Reporting to the CSO, the Senior Scientist, Formulation will work closely with the Formulation Team and will be responsible for designing and executing protocols related to internal and client-based projects, and subsequent data analysis. Our ideal candidate thrives on contributing collaboratively in a fast-paced, innovative environment and is open and interested in learning a variety of different research techniques...LEARN MORE

Scientist, Preclinical Development

This is a full-time Scientist role on the Preclinical Development team at Integrated Nanotherapeutics Inc. involving work across multiple sites: headquarters in Burnaby, BC, with in vivo research activities and flow cytometry conducted at sites in Vancouver, BC and flexibility for some remote work. The successful candidate will contribute to our R&D programs in antigen-specific immune tolerance by applying in vivo mouse and cellular immunology skills to develop and advance lead lipid nanoparticle-based products through preclinical pipelines...LEARN MORE

Biomanufacturing Trainer and Site Manager

Reporting to the Associate Director of Technical Training they will take a leadership role in overseeing the set-up and operations of the greater Vancouver Training Facility and supporting the company’s overall strategy. As an expert in the field of biopharmaceutical manufacturing and bioprocessing, the Biomanufacturing Trainer/Site Lead will work with the Associate Director of Technical Training and other company team members to deliver world-class in-person, virtual and practical hands-on training to a variety of learners...LEARN MORE

TMX, comprising of the Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSXV) (the “Exchange”), provide companies with access to equity capital and the benefits of being listed on a leading global exchange with integrity, liquidity and opportunity. Companies listed on TSX and TSXV have access to North American capital markets, one of the world’s largest capital pools.

With a wide investor base providing liquidity, our Exchanges also serve as access points to the international pools of capital for companies seeking growth and expansion capital. Across our TSX and TSXV, we have over $25 Billion in market capitalization of Life Sciences listed issuer companies. LEARN MORE

Stay current by subscribing to this and our events newsletter!

Follow LSBC on Social Media!